N
KERX

Natixis’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Natixis’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,164
Closed -$79K – 1338
2017
Q3 		$79K Buy
+11,164
New +$80.3K ﹤0.01% 1198
2014
Q4 		– Sell
-14,300
Closed -$197K – 449
2014
Q3 		$197K Buy
+14,300
New +$219K ﹤0.01% 389

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Natixis's KERX Position: Q4 2017 in Review

Natixis sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 11,164 shares — an estimated $79K sold.

Natixis first reported a position in KERX in Q3 2014 and held it in 2 quarters. The position peaked at $197K in Q3 2014. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

  • Natixis reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Natixis sold 11,164 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $79K.
  • Natixis first reported a position in Keryx Biopharmaceuticals Inc in Q3 2014 and held it in 2 quarters.
  • Natixis's Keryx Biopharmaceuticals Inc position peaked at $197K in Q3 2014.
  • 129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on Natixis's 13F filing for Q4 2017, filed 14 Feb 2018.